Please collect the sea enterprises! Names and Websites of National and Regional Food and Drug Administration in Southeast Asia (Encyclopedia)
Release time:
2024-10-25
Durst DST continues to pay attention to the drug regulatory policies of countries around the world to help companies go to sea, and the following is the drug regulatory situation in Southeast Asian countries and regions.
Durst DST continues to pay attention to the drug regulatory policies of countries around the world to help companies go to sea, and the following is the drug regulatory situation in Southeast Asian countries and regions.

1. Singapore Health Sciences Board (Health Sciences Authority):www.hsa.gov.sg
2. National Drug Regulatory Authority of Malaysia (National Pharmaceutical Regulatory Agency):www.npra.gov.my
3. Food and Drug Administration of Thailand: www.fda.moph.go.th
4. Indonesian Food and Drug Administration (National Agency of Drug and Food Control):www.ponlokkes.go.id
5. Food and Drug Administration of the Philippines: www.fda.gov.ph
Drug Administration of Vietnam: www.dav.gov.vn
7. Taiwan (China): Department of Food and Drug Administration, Ministry of Health and Welfare, https://www.fda.gov.tw/
8. Hong Kong (China): Drug Office, Department of Health,
https://www.drugoffice.gov.hk/
6. Cambodia: Ministry of Health, Drug and Food Administration of Cambodia, http://www.moh.gov.kh/
7. Myanmar: Myanmar Food and Drug Administration, https://www.fda.gov.mm/
8. East Timor: National Drug and Medical Device Authority, Ministry of Health, East Timor, https://www.moh.gov.tl/
9. Laos: Department of Food and Drugs, Ministry of Health, https://www.moh.gov.la/
10. Sri Lanka: National Drug Administration of Sri Lanka, https://www.npa.gov.lk/
11. Brunei: Department of Pharmaceutical Services, Ministry of Health, Brunei Darussalam, https://www.moh.gov.bn/
These authorities are responsible for overseeing drugs and medical devices in their respective countries to ensure their safety, effectiveness and quality. Their websites provide resources and information on drug registration, regulatory policies, safety information, and more.
It should be noted that the URL may change. It is recommended to confirm the latest URL through official channels or search engines when using it. In addition, the FDA in different countries may have different names and organizational structures, which may vary from country to country. If you need more detailed and accurate information, it is recommended to visit the official website of the relevant FDA directly or contact the local regulatory agency.
Key words:
Related Blog
Durst DST Regulation Group, noting that on July 1, 2024, the Drug Evaluation Center of the State Drug Administration (hereinafter referred to as CDE) issued a trial notice on the submission of electronic application materials for drug registration by network transmission. Starting from July 1, 2024, the trial work on the network transmission of electronic application materials for drug registration will be started, and applicants can submit electronic application materials for drug registration through network transmission. There is also an attachment: the reservation for network transmission of electronic declaration materials and the description of operation steps, which is convenient to guide everyone to submit electronic declaration materials.
2024-07-05
Recently, after the products of DST DST customers Sichuan well-known pharmaceutical companies passed PAI inspection in November 2023, they were officially approved in December. In June 2024, they officially sent several batches of products to enter the US market. This exciting news came at the time of the third FDA project audit of the client again. The customer is located in Neijiang City, Sichuan Province, an ancient city between Chengdu and Chongqing. The success of Huiyu Pharmaceutical has made this city more attractive to pharmaceutical people! Once again, congratulations to the customer products officially go to sea! The entry of products into the US market shows that DST customers have been strictly implementing quality management according to high standards, continuously optimizing production processes, and producing more high-quality products higher than national standards.
2024-07-05
Recently, after the products of DST DST customers Sichuan well-known pharmaceutical companies passed PAI inspection in November 2023, they were officially approved in December. In June 2024, they officially sent several batches of products to enter the US market. This exciting news came at the time of the third FDA project audit of the client again. The customer is located in Neijiang City, Sichuan Province, an ancient city between Chengdu and Chongqing. The success of Huiyu Pharmaceutical has made this city more attractive to pharmaceutical people! Once again, congratulations to the customer products officially go to sea! The entry of products into the US market shows that DST customers have been strictly implementing quality management according to high standards, continuously optimizing production processes, and producing more high-quality products higher than national standards.
2024-07-05
Argument! Hengrui Warning Letter, Is It FDA's Political Sanction?
Tieguai Liu saw many posts about whether there were political factors in Hengrui's warning letter. Today, Tieguai Liu will discuss this matter with everyone's concerns. First of all, we are very sensitive to see that the "first brother" of China's pharmaceutical industry has received a warning letter from the FDA of the United States. For today's Sino-US environment, we naturally think of the FDA's sanctions against the first brother due to the influence of US politics. It is completely understandable from everyone's interpretation. The following Tieguai Liu will discuss with you from both positive and negative dimensions:
2024-10-25
Durst DST continues to pay attention to the drug regulatory policies of countries around the world to help companies go to sea, and the following is the drug regulatory situation in Southeast Asian countries and regions.
2024-10-25